Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE） (neoSCORE)

Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE）：A Prospective, Randomized, Open-Label, Single-Center Phase 2 Trial

This is a Phase 2, prospective, randomized, open-Label, single-center international study that assesses the efficacy and safety of neoadjuvant therapy with different cycles of sintilimab combined with chemotherapy for resectable NSCLC. This trial will also explore the biomarkers of neoadjuvant immunochemotherapy.

Study Overview

• Status: Active, not recruiting
• Conditions: Non-small Cell Lung Cancer
• Intervention / Treatment: Biological: sintilimab; Drug: pemetrexed; Drug: Carboplatin; Drug: albumin-bound paclitaxel

Detailed Description

This is a Phase 2, prospective, randomized, open-Label, single-center international study that assesses the efficacy and safety of neoadjuvant therapy with different cycles of sintilimab combined with chemotherapy for resectable NSCLC. In this trial, eligible subjects will be randomly assigned to arm A and arm B (1:1). Subjects in arm A will receive 2 cycles of neoadjuvant chemotherapy with sintilimab + chemotherapy and arm B will receive 3 cycles of neoadjuvant chemotherapy with sintilimab + chemotherapy, followed by surgery within the 4th week after the last dose of sintilimab. After operation, subjects in arm A will receive 2 cycles of adjuvant chemotherapy and arm B will receive 1 cycle of adjuvant chemotherapy, followed by the maintenance treatment of sintilimab for up to 1 year according to the requirements of patients. The primary purpose is MPR rate of neoadjuvant chemotherapy of resectable NSCLC with different cycles of sintilimab combined with platinum-based chemotherapy, which is defined as the percentage of participants having ≤10% viable tumor cells in the pathological examination of resected specimens.

• Study Type: Interventional
• Enrollment (Actual): 60
• Phase: Phase 2

Contacts and Locations

Study Locations

• China
  • Zhejiang
    • Hangzhou, Zhejiang, China, 310009
      • Second Affiliated Hospital, School of Medicine, Zhejiang University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Sign the informed consent form before starting any trial related procedure.
• 18-75 years old, male or female.
• Non-small cell lung cancer confirmed by cytology or histology.
• There must be at least one evaluable focus judged according to recist1.1 standard.
• Evaluation by the researchers to confirm resectable stage cⅠb-Ⅲa NSCLC patients without any treatment before.
• ECOG PS 0-1.
• Life expectancy > 6 months.

• Adequate organ function and it should meet the following criteria:

  1. No use of Granulocyte colony stimulating factor within 14 days, absolute neutrophils count(ANC)≥1.5x109/L, platelets count(PLT)>9g/dL, hemoglobin(HB)≥100×109/L;
  2. Total bilirubin(TBIL)≤1.5ULN, ALT、AST≤ 2.5 ULN, serum creatinine(sCr)≤1.5ULN;
  3. good blood coagulation: INR≤1.5 or PT≤1.5 ULN;
  4. normal thyroid function: TSH within normal institutional limits;
• Women of childbearing age must undergo a serological pregnancy test within 3 days before the first dose(cycle 1 day 1) with negative results. If the result of urine pregnancy test cannot be confirmed as negative, blood pregnancy test is required.

Exclusion Criteria:

• Malignancies within 5 years prior to the first dose(excluding radical skin basal cell carcinoma, skin squamous cell carcinoma and / or radical resection of carcinoma in situ).
• Currently participating in the intervention clinical treatment, or receiving other drugs or research instruments within 4 weeks before the first dose.
• Patients who have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or drugs for another stimulation or synergistic inhibition of T cell receptor (e.g. CTLA-4, OX-40, CD137).
• Active autoimmune diseases requiring systemic treatment (e.g. using disease improving drugs, corticosteroids or immunosuppressants) occurred within 2 years before the first dose. Alternative therapies (e.g. thyroxine, insulin or corticosteroids in physiological doses for adrenal or pituitary insufficiency) are not considered systemic treatment.
• Systemic glucocorticoid therapy (excluding local glucocorticoids by nasal spray, inhalation or other routes) or any other form of immunosuppressive therapy is in progress within 7 days before the first dose.

Note: it is allowed to use physiological dose of glucocorticoid (Prednisone≤10 mg/d or equivalent drug).

• Received allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation.
• Allergic to study drug(sintilimab, pemetrexed, carboplatin, albumin-bound paclitaxel) components excipients.
• Not fully recovered from toxicity and/or complications caused by any intervention before treatment (≤level 1 or reach baseline, excluding fatigue or hair loss).
• Has a known history of human immunodeficiency virus (HIV) infection (HIV 1/2 antibody positive).
• Untreated active Hepatitis B (defined as HBsAg positive and HBV-DNA copies>ULN).
• Active Hepatitis C (HCV antibody positive and HCV-RNA level higher than the detection limit).
• Inoculate the live vaccine within 30 days before the first dose (cycle 1 day 1).

Note: it is allowed to receive the injection inactivated virus vaccine for seasonal influenza within 30 days before the first dose; however, it is not allowed to accept the live attenuated influenza vaccine for intranasal medication.

• Pregnant or lactating women.

• There are any serious or uncontrollable systemic diseases, such as:

  1. Resting ECG has significant abnormalities in rhythm, conduction or morphology, and the symptoms are serious and difficult to control,such as complete left bundle branch block, heart block above degree Ⅱ, ventricular arrhythmia or atrial fibrillation;
  2. Unstable angina, congestive heart failure, chronic heart failure with NYHA grade ≥ 2;
  3. Within 6 months before inclusion, there were any arterial thrombosis, embolism or ischemia, such as myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic attack etc;
  4. History of noninfectious pneumonia requiring glucocorticoid treatment within 1 year before the first dose,or having currently clinical active interstitial lung diseases;
  5. Active pulmonary tuberculosis;
  6. Active or uncontrolled infections requiring systemic treatment;
  7. Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis;
  8. poorly controlled diabetes (Fasting blood glucose (FBG)>10mmol/L);
  9. Urine routine test indicates that urine protein≥++, and confirmed that 24 hours proteinuria>1.0 g;
  10. Patients with mental disorders who are unable to cooperate with the treatment;
• There are medical history, disease, treatment or laboratory abnormal results that may interfere with the test results, prevent the subjects from participating in the whole process of the study, or the researchers think that participating in the study is not in the best interests of the subjects or there are other potential risks that the subjects are not suitable for the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: sintilimab+chemotherapy(2 cycles of neoadjuvant chemotherapy); Patients with nonsquamous NSCLC (including adenocarcinoma, large cell carcinoma and unspecified type) : sintilimab + pemetrexed + carboplatin; Patients with squamous NSCLC : sintilimab + albumin-bound paclitaxel + carboplatin; Followed by surgery within the 4th week after the second dose of sintilimab; Followed by 2 cycles of adjuvant chemotherapy, the researcher will decide whether to radiotherapy or not according to the clinical situation and pathological stage of the patient; Followed by the maintenance treatment of sintilimab for up to 1 year according to the requirements of patients.	Biological: sintilimab; 200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.; Other Names: IBI308; PD-1 antibody; Drug: pemetrexed; 500 mg/m^2 by IV infusion Q3W, given on cycle day 1.; Drug: Carboplatin; AUC 5 mg/mL/min by IV infusion Q3W, given on cycle day 1.; Drug: albumin-bound paclitaxel; 260 mg/m^2 by IV infusion Q3W, given on cycle day 1.
Experimental: sintilimab+chemotherapy(3 cycles of neoadjuvant chemotherapy); Patients with nonsquamous NSCLC (including adenocarcinoma, large cell carcinoma and unspecified type) : sintilimab + pemetrexed + carboplatin; Patients with squamous NSCLC : sintilimab + albumin-bound paclitaxel + carboplatin; Followed by surgery within the 4th week after the third dose of sintilimab; Followed by 1 cycles of adjuvant chemotherapy, the researcher will decide whether to radiotherapy or not according to the clinical situation and pathological stage of the patient; Followed by the maintenance treatment of sintilimab for up to 1 year according to the requirements of patients.	Biological: sintilimab; 200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.; Other Names: IBI308; PD-1 antibody; Drug: pemetrexed; 500 mg/m^2 by IV infusion Q3W, given on cycle day 1.; Drug: Carboplatin; AUC 5 mg/mL/min by IV infusion Q3W, given on cycle day 1.; Drug: albumin-bound paclitaxel; 260 mg/m^2 by IV infusion Q3W, given on cycle day 1.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Major pathological response rate (MPR)	MPR rate is defined as the percentage of participants having ≤10% viable tumor cells in the pathological examination of resected specimens.	At time of surgery

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pathology complete response rate(pCR)	pCR rate is defined as the percentage of participants lacking of evidence of viable tumor cells in the pathological examination of resected specimens.	At time of surgery
Objective response rate (ORR)	ORR is defined as the percentage of participants having a complete response or a partial response, measured by RECIST 1.1.	prior to surgery
2 years disease-free survival rate (DFS)	2 years DFS rate is defined as the percentage of participants having no recurrence, distant metastasis or death within 2 years after operation.	2 years postoperatively
2 years overall survival rate (OS)	2 years OS rate is defined as the percentage of participants having no death of any cause within 2 years after operation.The Kaplan-Meier estimator will be used to estimate median OS and its 95%CI and the survival curve.	2 years postoperatively

Collaborators and Investigators

• Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2020
• Primary Completion (Actual): November 1, 2021
• Study Completion (Anticipated): July 1, 2023

Study Registration Dates

• First Submitted: July 2, 2020
• First Submitted That Met QC Criteria: July 2, 2020
• First Posted (Actual): July 7, 2020

Study Record Updates

• Last Update Posted (Actual): July 12, 2022
• Last Update Submitted That Met QC Criteria: July 11, 2022
• Last Verified: September 1, 2021

More Information

Terms related to this study

• Keywords: sintilimab; resectable NSCLC; neoadjuvant immunochemotherapy
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Molecular Mechanisms of Pharmacological Action; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Phytogenic; Folic Acid Antagonists; Carboplatin; Paclitaxel; Albumin-Bound Paclitaxel; Pemetrexed
• Other Study ID Numbers: 2020-KYY-518052-0092

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No